SCHEMBL10243833

SCHEMBL10243833

CCN(CCNC(=O)OC)C(C)c1cccc(F)c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 3/20 0.43
CYP2D6 P10635 2/20 0.43
CYP2C9 P11712 2/20 0.43
ALOX15 P16050 1/20 0.43
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
OPRL1 P41146 6/20 0.39
OPRM1 P35372 3/20 0.39
HDAC4 P56524 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC5 Q9UQL6 1/20 0.38
TSHR P16473 1/20 0.38
KDM4E B2RXH2 1/20 0.38
AOC3 Q16853 1/20 0.37
FAAH O00519 1/20 0.37
BCHE P06276 1/20 0.37
ACHE P22303 1/20 0.37
GPR139 Q6DWJ6 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10244077 0.87 CYP2C19 (0.42) CYP2C19CYP2D6CYP2C9KMT2AAOC3
SCHEMBL10243821 0.87 OPRK1 (0.46) OPRM1TSHRKDM4EFAAHBCHE
SCHEMBL10243851 0.86 MTNR1A (0.47) FAAHBCHEACHE
SCHEMBL10244397 0.86 MTNR1A (0.47) FAAHBCHEACHE
SCHEMBL10243869 0.86 BCHE (0.37) CYP2C19CYP2D6CYP2C9ALOX15FAAH
SCHEMBL10243444 0.86 RAB9A (0.45) CYP2C19CYP2C9ALOX15MEN1KMT2A
SCHEMBL10243429 0.86 MTNR1A (0.47) FAAHBCHEACHE
SCHEMBL10243624 0.86 ACHE (0.37) CYP2C19CYP2D6TSHRKDM4EFAAH
SCHEMBL10243614 0.85 MCHR1 (0.42) CYP2C9MEN1KMT2AKDM4EGPR139
SCHEMBL10243623 0.85 HPGD (0.40) CYP2C19CYP2D6CYP2C9TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 CYP2C19 262/4885CYP2D6 1574/4885CYP2C9 395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.